Latin America is set to gain more and more momentum as a possible destination for clinical trials
"One of the first major aspects of the region is that it has a growing population and a population which at the same time exhibits many of the major diseases seen in other global regions," explained Dr Kermani. "There have been notable increases in several Latin American countries of chronic diseases, particularly viral, cardiovascular, respiratory and metabolic conditions, and yet a persistence of diseases associated with poverty and social inequality."
Ironically, despite the persistence of these diseases, it is the ever improving economic situations in countries such as Brazil, Mexico and Argentina that gives the region the more solid footing which will inevitably make the process of selecting it as a clinical trial destination easier for the key manufacturers.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.